| CAS | 79517-01-4 |
| Sequence | H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol (Disulfide bond) |
| Sequence Single | fCFwKTC-L-threoninol |
| Molecular Formula | C49H66N10O10S2 |
| Molecular Weight | 1019.26 |
| Synonyms | SMS 201-995, (D-Phe5,Cys6.11,D-Trp8,L-Threoninol12)-Somatostatin-14 (5-12) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research |
| Description | Octreotide also called SMS 201-995, (D-Phe5,Cys6.11,D-Trp8,L-Threoninol12)-Somatostatin-14 (5-12), a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently. |
| References | 1. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. C.E.Touloukian et al., J. Immunol., 164, 3535 (2000) 2. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures. G.Melacini et al., Biochemistry, 36, 1233 (1997) 3. Octreotide. S.W.Lamberts et al., N. Engl. J. Med., 334, 246 (1996) 4. Intrarenal octreotide treatment prevents sodium retention in liver cirrhotic rats: evidence for direct effects within the thick ascending limb of Henle’s loop. T.E.Jonassen et al., Am. J. Physiol. Renal Physiol., 291, F537 (2006) 5. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. S.Grozinsky-Glasberg et al., Neuroendocrinology, 87, 168 (2008) 6. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. Wang M, et al. J Control Release. 2016 May 28;230:45-56. 7. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. Kim S, et al. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12. |